register

Social Responsibility

Sanofi celebrates 30 years of rare disease Humanitarian Program

Health Industry Hub | September 24, 2021 |
[Total: 1    Average: 5/5]

Social Responsibility: Sanofi employees across Australia and New Zealand joined members of the rare disease community, to recognise this year’s 30th anniversary of Sanofi Genzyme’s Humanitarian Program.

The initiative began under the leadership of Genzyme founder Henri Termeer, a visionary who recognised not only the need to develop ground-breaking treatments for patients but also to help ensure equity of access.

The first and longest running humanitarian initiative of its type, the 30th anniversary of Sanofi Genzyme’s Humanitarian Program is a significant milestone that marks the company’s commitment, responsibility and hope for people living with five different lysosomal storage disorders (LSDs), a group of rare genetic conditions caused by enzyme deficiencies, as well as patients with haemophilia, a rare genetic disorder in which a person’s blood does not clot normally. 

Sanofi Genzyme Australia and New Zealand General Manager, Fiona Clark said “While the Program has evolved over the past 30 years, it has always retained its core commitment: to provide access to free treatment for patients, that meet the program’s criteria, who otherwise would not have access.

“With more than 1000 people across the world, including Australia and New Zealand currently being supported on the program, this anniversary is something that all of our people can be proud of.”

To recognise the milestone, Sanofi hosted an interactive webinar for Australia and New Zealand employees who heard first-hand stories from people living with a rare disease and the impact this program has had on their lives.

Allyson Lock, President of the New Zealand Pompe Network and recipient through the Humanitarian Program, was diagnosed with Late Onset Pompe Disease over a decade ago and like many patients living with a rare disease it took Allyson many years of searching before she received a diagnosis of Pompe.

“The day I received the call that I had been given access to compassionate treatment truly altered the course of my life. Today I continue to live life to its fullest – being a mother to my boys, working on my property and running my patient group. Without treatment none of this would be possible and I am forever grateful.”


Human Resources

PAIG co-chairs reflect on industry progress in D&I with sights set on next phase goals

Health Industry Hub | January 17, 2022 |

Human Resources: In this Health Industry Hub podcast, Medicines Australia’s PAIG (Pharma Australia Inclusion Group) co-chairs reflect on their contribution […]

More


News & Trends - Medical Technology

MedTech News -

Stryker announces fellowships for medtech partner projects

Health Industry Hub | January 17, 2022 |

MedTech News: Stryker announced two of its partner research projects have secured fellowship funding from the Australian government’s Researcher Exchange […]

More


News & Trends - Pharmaceuticals

Pharma News - New guidelines recommend Eli Lilly and GSK drugs in treating COVID-19 patients

New guidelines recommend Eli Lilly and GSK drugs in treating COVID-19 patients

Health Industry Hub | January 17, 2022 |

Pharma News: Update to international guidelines recommend two new drugs for the treatment of COVID-19. Eli Lilly’s oral JAK inhibitor, […]

More


News & Trends - Pharmaceuticals

Pharma News -

Novartis shifts focus as CAR T-cell therapy fails to add benefit in non-Hodgkin lymphoma

Health Industry Hub | January 17, 2022 |

Pharma News: Novartis’ chimeric antigen receptor (CAR) T-cell therapy was not found to improve event-free survival over what was seen […]

More